IP Group is a leading intellectual property commercialisation company which focuses on evolving ideas from its partner universities and turn these into businesses. They are helping to create, build, and support early-stage to mature businesses across Life Sciences, Cleantech and Technology. IP Group is supporting their portfolio companies with financial capital, strategic and commercial expertise, executive search and development, corporate finance and and capital raising, and a range of administrative services. The Group began their long-term partnership model with United Kingdom universities and replicated this approach in research institutions in United States and in 2017, they expanded into Australasia.
DNA sequencing company specializing in rapid long-read sequencing through nanopores.
A technology company designing and manufacturing diffractive waveguides for augmented reality devices.
A technology company making mid-air haptics for creating three-dimensional shapes and textures that can be felt.
Import.io is a Los Gatos, California-based company founded in 2012 by David White.
A clinical cancer genomics company using liquid biopsy in cancer patients
Artios Pharma develops cancer treatments that target DNA Damage Response (DDR) Pathways to selectively kill cancer cells
TheySay is a London-based artificial intelligence company.
Carisma Therapeutics is a Philadelphia County, Pennsylvania-based company.
Chief Executive Officer
Chief Operating Officer
Dr Elaine Sullivan
Chief Financial Officer
Chief Investment Officer
Prof David Begg
Senior Independent Director
Sir Douglas Flint, CBE
Documentaries, videos and podcasts
Actual Experience plc
Autifony Therapeutics Ltd
Charles H. Large, PhD
Developing high value, novel medicines to treat serious diseases of the central nervous system
Cell Medica Ltd
Cellular immunotherapy products for the treatment of cancer and infections
Ceres Power Holdings plc
Ceramic fuel cell technology for distributed generation
Specialty pharmaceutical company focused on respiratory disease
A global pharmaceutical company focused on chronic endocrine conditions
Design and development of novel therapeutic drugs
Dr Gordon Sanghera
Electronics-based DNA/RNA sequencing technology
Oxford Sciences Innovation plc
Commercialization of intellectual property from the University of Oxford
PsiOxus Therapeutics Ltd
Dr John Beadle
Systemic delivery of tumour-targeted oncolytic immune therapeutics